PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that r...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzubi, Jamal, Dettmer-Monaco, Viviane, Kuehle, Johannes, Thorausch, Niko, Seidl, Maximilian, Taromi, Sanaz, Schamel, Wolfgang, Zeiser, Robert, Abken, Hinrich, Cathomen, Toni, Wolf, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372156/
https://www.ncbi.nlm.nih.gov/pubmed/32728611
http://dx.doi.org/10.1016/j.omto.2020.06.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372156/
https://www.ncbi.nlm.nih.gov/pubmed/32728611
http://dx.doi.org/10.1016/j.omto.2020.06.014

Ejemplares similares